A line-by-line read of the FY2025 Integrated Annual Report plus the Q1 2026 interim results: what the disclosures actually show on the credit ratings, margins, the investment-cycle engine behind the profit, the related-party associate that just flipped to a loss, the ~98% dividend pipe to the Schaffter holding company, and whether the "Beyond the Summit" story matches the numbers.
Start with the freshest data, because it settles the argument. In Q1 2026 (quarter ended 31 March), gross written premium grew an even faster +42% to LKR 2.60 Bn — and net profit fell 61% to LKR 114 Mn (from LKR 292 Mn). The clearest single cause: the company's 25% stake in sister-company First Capital swung from a +LKR 128 Mn profit to a −LKR 120 Mn loss, while its own investment income fell 23% and realised gains collapsed 89%. Premiums up two-fifths, profit down nearly two-thirds — that is the whole company in one quarter.
It confirms the FY2025 pattern: GWP +31% to a record LKR 8.65 Bn, yet PBT −31% and PAT −23%. Janashakthi earns more from its investment book (and a related-party associate) than from underwriting, and as rates normalised, both reversed. Underneath sits genuine strength — solvency (CAR 284% vs a 120% floor), a life fund still compounding (+4% in the quarter alone), and positive operating cash flow — set against a ~98% dividend payout that pipes cash up to a 74.24% parent rated two notches below the insurer, a ~20% public float, and a stock that re-rated to ~1.8× book just as ROE and profit turned down. Real franchise, real solvency — but earnings quality, capital allocation and valuation all now carry fresh, dated evidence against them.
Company = Group (life-only insurer). Year ended 31 December 2025 vs 2024. Source: FY2025 Integrated Annual Report.
Premiums accelerated. Profit collapsed. In a single quarter, Janashakthi grew GWP +42% and reported net profit −61%. If you wanted proof that this company's bottom line is driven by markets rather than underwriting, Q1 2026 is it.
Note also: no surplus was transferred from the life fund to the income statement in Q1 2026, so this quarter's weak profit is "clean" of surplus-transfer support. Source: Interim Condensed Financial Statements, Q1 2026.
Net income (total revenue) barely moved — up 4% to LKR 13.75 Bn — because the 31% jump in premium was almost entirely offset by a 22% fall in investment-side revenue. Below the revenue line, claims, acquisition costs and overheads all rose. The result: a record top line and a materially smaller bottom line.
Bars are directional, scaled for readability — not to a common axis. The point is the shape: revenue mix shifted away from the high-margin investment gains that drove 2023–24, while the cost base grew.
Janashakthi's profit does not track its underwriting. It tracks the interest-rate and equity cycle. Look at five years of net profit against a steady premium base:
In 2022, mark-to-market losses on government bonds during the sovereign-debt crisis crushed profit to LKR 105 Mn (−88%). When yields then fell and bond prices recovered in 2023–24, the same portfolio threw off enormous gains and profit exploded above LKR 4 Bn. In 2025, rates stabilised, the fixed-income portfolio contracted, "total other revenue" fell to LKR 5.38 Bn (from 6.92 Bn), and profit followed it down. Premiums were never the volatile part — the investment book was.
It is not just the direct bond portfolio. On 29 December 2023 Janashakthi acquired a 25% stake in First Capital Holdings PLC — the Schaffter group's own listed investment bank (primary dealer, fixed-income, asset management) — and now books a share of its profit as equity-method "associate" income. First Capital's earnings are themselves driven by the bond cycle. So the insurer has two exposures to the same interest-rate engine: its own portfolio, and a related-party associate that does the same thing. In the good years both fire together; in 2025 they cooled together — and in Q1 2026 the associate flipped to a LKR 120 Mn loss (from a +128 Mn contribution), single-handedly larger than the quarter's entire pre-tax profit. The "two pipes" thesis is no longer theoretical; it is in the latest accounts.
Verify against primary sources: the precise investment-income / realised-gain / fair-value-gain split and the associate's full results sit in the notes to the accounts.
Two separate entities get rated, and conflating them is where the "AA / A-" confusion comes from:
| Entity | What it is | Latest rating | Trajectory |
|---|---|---|---|
| Janashakthi Insurance PLC JINS — the listed life insurer | Insurer Financial Strength (IFS) | A- (Stable) | Upgraded to A- by Lanka Rating Agency |
| Janashakthi Limited JXG — the 74.24% parent holdco | Issuer credit rating | BBB- | BB- → BBB- 3-notch upgrade, May 2024 (LRA) |
| Janashakthi Limited (prior) earlier agency view | Issuer credit rating | BB+ / neg | Sub-investment grade ICRA Lanka, 2022 |
So the answer to "what happened to their ratings, AA or A-?": the insurer is A-, recently upgraded — a genuine positive, reflecting the strong solvency cushion. But it was never AA. And the structurally interesting fact is that the regulated insurer (A-) is rated two notches above its own parent (BBB-, and that only after climbing out of junk in 2024). That gap is normal in form — regulated insurers ring-fence policyholder capital — but it sets up the tension in the next section: the higher-rated, cash-generative subsidiary is the dividend engine for the lower-rated holding company sitting on top of it.
This is the part worth slowing down on. Janashakthi paid out a record LKR 3.4 Bn dividend on LKR 3.47 Bn of profit — a payout ratio near 98%. Almost nothing was retained. Total equity actually fell (LKR 16.90 Bn → 16.64 Bn) and net assets per share went backwards (74.62 → 73.47), in a year management called record-breaking. For a "growth" life insurer that needs capital to fund new-business strain and its own 5-year doubling plan, paying out essentially all of profit is a choice — and the beneficiary structure is the point.
~LKR 3.4 Bn dividend flows up this pipe each year. The parent's own Group CFO has publicly attributed the holdco's strength to "healthy dividend inflows from prominent subsidiaries." In plain terms: the listed insurer's cash is a key fuel source for the lower-rated family holding company's de-leveraging and expansion ambitions. Minority shareholders of JINS receive the same high yield — but the capital-allocation priority is set by the controlling group, not the float.
Founder Chandra (C.T.A.) Schaffter; Prakash Schaffter is Executive Deputy Chairman (ran the company as MD from 2006, led the 2015 AIA-general acquisition and the 2018 general-insurance sale to Allianz); Ramesh Schaffter sits on the board and is JXG's Group MD/CEO. An independent Chairperson, Annika Senanayake, was installed on 1 Jan 2025 — a real governance improvement in form, though the family retains executive control and the votes. CEO Ravi Liyanage (ex-Richard Pieris / TVS) runs the business. The board was refreshed again with two new independent directors from 20 April 2026 — Jerome Hasitha Leanage and Hugh Edward Terry (a recognised insurtech figure) — adding outside expertise, which is a credible governance positive even as control stays with the group.
The genuinely encouraging operating signals:
The offsetting cost story:
The report's language is relentlessly peak-of-the-mountain: "conquered summits," "market leader," "sector outperformer." The disclosed market position is more modest — Janashakthi is the ~7th-largest life insurer in Sri Lanka with roughly 4% market share. It is a capable niche player growing off a small base (which is exactly why +61% new business is achievable), not the dominant force the prose implies.
Bars are illustrative scale, not a precise league table. The takeaway: read the achievement language against the 4% share. Small-base growth is real and valuable — but it is a different investment proposition than market leadership, and the multiple should reflect which one you're actually buying.
The customer signals are positive and improving, not stellar:
But the NPS breakdown is where the nuance lives:
Nearly a third of surveyed customers are detractors and CSAT sits at 69% — fine, not loved. Real digital progress (48-hour claims, AI underwriting, tri-lingual app, "Customer 360" CRM, zero reported privacy breaches) is the credible part of the story.
Commitments drawn from the FY2024 report's Deputy Chairman & CEO reviews and outlook, checked against FY2025 disclosures.
| FY2024 promise / target | FY2025 outcome | Status |
|---|---|---|
| 5-year plan to double market share / premium by 2029 | Year 1 strong: GWP +31%, new business +61%, renewals +17% | On track |
| Secure a credit-rating improvement | Upgraded to A- (Stable) by Lanka Rating Agency | Delivered |
| Keep capital adequacy well above the regulatory floor | CAR 284% vs 120% minimum | Delivered |
| Digital transformation (claims, app, underwriting) | 48-hr claims, AI underwriting, tri-lingual app, +58% app usage | Delivered |
| IFRS 17 / RBC transition (phase 1 done, phase 2 underway) | Still "remodelling the business" for IFRS 17 in 2025 | In progress |
| Maintain expense-ratio discipline / cost efficiency | NAC ratio rose 26%→30%; opex +22% | Slipped |
| Open 6 branches + 10 window offices in 2025 | Deferred to 2026 (HQ relocation); only a Kandy window office added | Missed / deferred |
| Convert top-line strength into profitability | PBT −31%, PAT −23% (investment-cycle reversal) | Fell |
| Bedded-in Deputy CEO (Niranjan Thangarajah, hired 2024) | No Deputy CEO in the FY2025 org chart — role appears to have lapsed | Churn |
Subjective weights reflect what drives durable value for a minority shareholder in a family-controlled life insurer. Weighted total ≈ 5.0 / 10.
For a life insurer, the cleaner lens than a DCF is the justified price-to-book: a bank/insurer is worth a premium to book only if its sustainable ROE beats its cost of equity. The relationship is Justified P/B = (ROE − g) ÷ (CoE − g). Move the sliders to see what the current ~LKR 44 price is implicitly assuming. This is a teaching tool, not a forecast or a target.
Confirmed inputs after the 1:3 subdivision: equity LKR 16.75 Bn ÷ 679,578,459 shares = NAV/share ~LKR 24.65, so ~LKR 44 ≈ 1.8× book. Trailing-twelve-month profit is ~LKR 3.3 Bn (FY2025 less Q1 2025 plus Q1 2026) → P/E ~9×; but if the weak Q1 2026 run-rate (LKR 114 Mn) were to persist, forward earnings would sit far below that — the multiple is only "cheap" if the investment cycle turns back up.
GWP, new business, dividend and share price all framed as records; PBT −31% / PAT −23% in FY2025 are stated but never foregrounded — and Q1 2026 widened the gap to GWP +42% / PAT −61%. The headline and the bottom line point in opposite directions, and the gap is growing.
LKR 3.4 Bn paid on LKR 3.47 Bn profit; equity shrank; book value flat. Cash is piped to the 74.24%-owner JXG (BBB-) which itself wants to list. Dividend is the return — book value is not compounding for minorities.
Profit swung 105 Mn → 4.5 Bn → 3.5 Bn on mark-to-market, not premium — then Q1 2026 PAT fell 61% as investment income (−23%) and realised gains (−89%) cooled. Capitalising near-peak investment profit at a premium multiple is the classic top-of-cycle trap.
The insurer owns 25% of the family's own investment bank (First Capital) and books its result via equity method. In Q1 2026 that line was a −LKR 120 Mn loss (from +128 Mn) — bigger than the whole quarter's pre-tax profit. And the ownership is circular: a First Capital entity owns 5.78% of the insurer in return.
The CEO/Finance review states ROE of 21% for 2025; the Financial Highlights infographic shows 28%. Given PAT fell and equity was flat, ~21% is the arithmetic answer. A small but telling disclosure-quality slip.
The +61% new business came with rising acquisition and admin costs. Watch year-2 persistency to see whether that spend converts to durable renewal income.
The achievement language outruns the disclosed market position. Small-base growth is real; market leadership is not what the numbers show.
The 2024-hired Deputy CEO is absent from the 2025 org chart, and the promised 6 branches + 10 window offices were pushed to 2026. Execution slipped against last year's plan.
Group holds ~80% (JXG 74.24% + First Capital 5.78%), leaving a ~20% public float; beta ~1.59 and the fresh 1:3 subdivision mean the price is sentiment-sensitive. A momentum-driven re-rating can unwind the same way.
Full adoption lands in Q4 2026 and the FY2026 accounts (with 2025 restated). "Gross written premium" as a revenue headline largely disappears, replaced by insurance revenue and CSM-based profit emergence. The metric the company leads with today won't exist in the same form next year — model the transition, don't extrapolate the current presentation.
You have a genuine asset: an A- insurer with a 284% CAR, a compounding life fund and real digital execution. The market's discount to that quality is about earnings quality and capital allocation, not solvency. Six things, in priority order:
For an insurer this becomes underwriting surplus vs investment gains. JAT's flattering tax line — Janashakthi's flattering investment cycle — both inflate a headline the operating engine didn't earn.
JAT hid segment profit; Janashakthi foregrounds "record GWP / dividend" and downplays −23% PAT, the associate, and a ~4% share. Read for the quiet line, not the loud one.
"Transformative" Mirotone — "Beyond the Summit." In both, the adjectives run ahead of the disclosed scale.
Credit the real strengths first (JAT's 57% coatings share; Janashakthi's 284% CAR), then press the structural issue (operating leverage / cash extraction).
JAT's DCF — Janashakthi's justified-P/B: both stocks embed an optimistic forward number while the latest results moved the other way.
JAT's 65% founder / ~14% float — Janashakthi's 74% parent. Thin floats make prices jumpy and put capital-allocation priorities in family hands.